Replies to post #108188 on Biotech Values

[zipjet]

The US Copaxone market accounts for more than 20% of Teva’s company-wide profits. The exact number is not disclosed, but it’s much closer to 30% than 20%, IMO. Note that Teva no longer pays SNY a 25% cut for co-marketing.

Actually I knew that and selected my variables to suggest a conservative answer.

Biomaven also took issue in the same direction.

:-)

This just makes Bio's hedging idea more compelling.

ij